Premium
Buccal delivery of insulin: the time is now
Author(s) -
Bernstein Gerald
Publication year - 2006
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20131
Subject(s) - buccal administration , medicine , postprandial , prediabetes , insulin delivery , insulin , diabetes mellitus , intensive care medicine , macrovascular disease , drug delivery , type 2 diabetes , endocrinology , pharmacology , type 1 diabetes , chemistry , organic chemistry
The burgeoning numbers of individuals with diabetes mellitus and prediabetes, in particular Type 2 including large numbers of children, open up not only the classic risks for microvascular disease but the earlier and incapacitating risk for macrovascular disease. Oral hypoglycemic agents and insulin sensitizers have not been adequate to control postprandial glucose. Prandial insulin is most desirable but resistance to injections limits its use. This has led to a battery of needle‐free insulin delivery systems. Buccal delivery stands out as being safe, simple, fast, flexible, and familiar to patient and physician alike. Drug Dev. Res. 67:597–599, 2006. © 2006 Wiley‐Liss, Inc.